- Home
- INTS
as 02-21-2025 4:00pm EST
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | SHELTON |
| Market Cap: | 33.4M | IPO Year: | 2023 |
| Target Price: | $8.50 | AVG Volume (30 days): | 24.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.18 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.50 - $5.94 | Next Earning Date: | 03-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Intensity Therapeutics Inc. Common stock News
INTS Breaking Stock News: Dive into INTS Ticker-Specific Updates for Smart Investing
PR Newswire
25 days ago
Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review
PR Newswire
a month ago
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
MT Newswires
2 months ago
Intensity Therapeutics Says Stockholder Armistice Capital May Sell 1.24 Million Shares
TipRanks
2 months ago
Intensity Therapeutics reports positive results of INT230-6 in breast cancer
MT Newswires
2 months ago
Intensity Therapeutics Says Cancer Drug Candidate Shows Benefits in Phase 2 Trial
PR Newswire
2 months ago
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
PR Newswire
3 months ago
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
PR Newswire
3 months ago
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Compare INTS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "INTS Intensity Therapeutics Inc. Common stock - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.